KRAS and cancer: Therefore, we hypothesize that the sensitivity of KRAS G13D mutant cancer cells to SHP2 inhibitors might be associated with the basal RAS activity or MEK/MAPK activation, the response to the upstream regulator–mediated nucleotide exchange and the rate of GAP-stimulated GTP hydrolysis of cancer cells.